Subsequently, we grouped the JMML cases according to the most prevalent molecular subtypes in our cohort of patients (PTPN11, KRAS and NRAS) and compared each group individually with the controls. The gene discussed is KRAS; the disease is juvenile myelomonocytic leukemia.